Literature DB >> 12584188

Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73.

Thorsten Stiewe1, Jens Stanelle, Carmen C Theseling, Barbara Pollmeier, Michaela Beitzinger, Brigitte M Pützer.   

Abstract

The p53 family includes three members that share significant sequence homology, yet exhibit fundamentally different functions in tumorigenesis. Whereas p53 displays all characteristics of a classical tumor suppressor, its homologues p63 and p73 do not. We have previously shown, that NH(2)-terminally truncated isoforms of p73 (Delta TA-p73), which act as dominant-negative inhibitors of p53 are frequently overexpressed in cancer cells. Here we provide evidence that Delta TA-p73 isoforms also affect the retinoblastoma protein (RB) tumor suppressor pathway independent of p53. Delta TA-p73 isoforms inactivate RB by increased phosphorylation, resulting in enhanced E2F activity and proliferation of fibroblasts. By inactivating the two major tumor suppressor pathways in human cells they act functionally analogous to several viral oncoproteins. These findings provide an explanation for the fundamentally different functions of p53 and p73 in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584188     DOI: 10.1074/jbc.M300357200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis.

Authors:  Piyali Dasgupta; Jiazhi Sun; Sheng Wang; Gina Fusaro; Vicki Betts; Jaya Padmanabhan; Saïd M Sebti; Srikumar P Chellappan
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

Review 2.  A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Authors:  D Engelmann; C Meier; V Alla; B M Pützer
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

3.  TAp73 induction by nitric oxide: regulation by checkpoint kinase 1 (CHK1) and protection against apoptosis.

Authors:  Ali Tebbi; Olivier Guittet; Marie-Hélène Cottet; Marie-Françoise Vesin; Michel Lepoivre
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

4.  deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.

Authors:  Oleksi Petrenko; Alexander Zaika; Ute M Moll
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

5.  Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway.

Authors:  Margareta T Wilhelm; Alessandro Rufini; Monica K Wetzel; Katsuya Tsuchihara; Satoshi Inoue; Richard Tomasini; Annick Itie-Youten; Andrew Wakeham; Marie Arsenian-Henriksson; Gerry Melino; David R Kaplan; Freda D Miller; Tak W Mak
Journal:  Genes Dev       Date:  2010-03-01       Impact factor: 11.361

Review 6.  p73 as a pharmaceutical target for cancer therapy.

Authors:  Andrea Bisso; Licio Collavin; Giannino Del Sal
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.

Authors:  Stephan Emmrich; Weiwei Wang; Katja John; Wenzhong Li; Brigitte M Pützer
Journal:  Mol Cancer       Date:  2009-08-11       Impact factor: 27.401

8.  Proinflammatory cytokines and bile acids upregulate ΔNp73 protein, an inhibitor of p53 and p73 tumor suppressors.

Authors:  Elena Zaika; Vikas Bhardwaj; Jinxiong Wei; Mary Kay Washington; Rhonda Souza; Wael El-Rifai; Alexander Zaika
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  TFF1 activates p53 through down-regulation of miR-504 in gastric cancer.

Authors:  Mohammed Soutto; Zheng Chen; Mohamed A Saleh; Ahmed Katsha; Shoumin Zhu; Alexander Zaika; Abbes Belkhiri; Wael El-Rifai
Journal:  Oncotarget       Date:  2014-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.